A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: hold back (279), keep back (403), deny (12)

Ibrutinib-Venetoclax

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia IBRUTINIB-VENETOCLAX Regimen CLL – Ibrutinib & Venetoclax Indication • Ibrutinib plus Venetoclax is recommended as an option for
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Ibrutinib-Venetoclax-Ver1.1.pdf

BRC Research-imaging-proposal-form_v2 2025 FINAL

Description
BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of an
Url
/Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v2-2025-FINAL.docx

Papers Trust Board - 11 November 2025

Description
Date Time Location Chair Agenda Trust Board – Open Session 11/11/2025 9:00 - 13:00 Conference Room, Heartbeat Education Centre
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-11-November-2025.pdf

BRC Research-imaging-proposal-form_v1 FINAL 10.12.2024

Description
BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of an
Url
/Media/Southampton-Clinical-Research/Grants/Download/BRC-Research-imaging-proposal-form-v1-FINAL-10.12.2024.docx

BRC Research-imaging-proposal-form_v1 FINAL 10.12.2024

Description
BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of an
Url
/Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v1-FINAL-10.12.2024.docx

BV-CHP Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Ver1

Description
Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE (BV-CHP) Regimen • Lymphoma – Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Indication Brentuximab vedotin in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BV-CHP-Brentuximab-vedotin-cyclophosphamide-doxorubicin-prednisolone.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

Isatuximab VRD weekly

Description
Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Re
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description
Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone In
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

DH IVIg approved indications full guidance July 2011

Description
DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Target Audienc
Url
/Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf
191 to 200 of 211
Previous … 18 19 20 21 22 Next